​

Nautilus Bio Stock (NASDAQ:NAUT)

ForecastOwnershipFinancialsChartTranscripts
Nautilus Bio by TradingView

Previous Close

$2.26

52W Range

$0.62 - $4.31

50D Avg

$2.75

200D Avg

$2.05

Market Cap

$290.38M

Avg Vol (3M)

$392.73K

Beta

0.75

Div Yield

-

NAUT Company Profile

Nautilus Biotechnology, Inc. is an emerging life sciences firm dedicated to pioneering a platform technology aimed at quantifying and comprehensively understanding the intricate complexities of the proteome. Their flagship offering, the Nautilus Platform, is an integrated proteomics system. It provides a complete, end-to-end solution, including specialized instruments, essential consumables, and advanced software for data analysis. Based in Seattle, Washington, the company was established in 2016.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

134

IPO Date

Aug 07, 2020

Website

NAUT Performance

NAUT Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-81.48M$-76.15M
Net Income$-59.00M$-70.78M$-63.67M
EBITDA-$-64.43M$-74.30M
Basic EPS$-0.47$-0.56$-0.51
Diluted EPS$-0.47$-0.56$-0.51

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q1 26Apr 28, 26 | 12:00 AM
Q4 25Feb 26, 26 | 8:30 AM
Q3 25Oct 28, 25 | 8:30 AM

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
ARCTArcturus Therapeutics Holdings Inc.
PYXSPyxis Oncology, Inc.
ENTAEnanta Pharmaceuticals, Inc.
TNYATenaya Therapeutics, Inc.
HUMAHumacyte, Inc.
ASMBAssembly Biosciences, Inc.
SGMTSagimet Biosciences Inc.
IMRXImmuneering Corporation
ZURAZura Bio Limited